Last reviewed · How we verify
MH004 1.0% Ointment
At a glance
| Generic name | MH004 1.0% Ointment |
|---|---|
| Sponsor | Minghui Pharmaceutical (Hangzhou) Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis (PHASE3)
- MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis (PHASE1, PHASE2)
- Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MH004 1.0% Ointment CI brief — competitive landscape report
- MH004 1.0% Ointment updates RSS · CI watch RSS
- Minghui Pharmaceutical (Hangzhou) Ltd portfolio CI